10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005)

Stephen L. Hauser; Ludwig Kappos; Massimo Filippi; Jerry S. Wolinsky; Martin S. Weber; Jacqueline Nicholas; Cathy Chognot; Hans‐Martin Schneble; Qīng Wáng; Gavin Giovannoni; Xavier Montalbán

doi:10.1212/wnl.0000000000205584

Related publications

Article2017

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Maria A. Rocca, Maria Pia Sormani, Marco Rovaris, Domenico Caputo, Angelo Ghezzi, Enrico Montanari, Antonio Bertolotto, Alice Laroni, Roberto Bergamaschi, Vittorio Martinelli, Gıancarlo Comı, Massimo Filippi

Article2023

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)

Clara Grazia Chisari, Assunta Bianco, Vincenzo Brescia Morra, Massimiliano Calabrese, Fioravante Capone, Paola Cavalla, Carlotta Chiavazza, Cristoforo Comi, Maura Danni, Massimo Filippi, Pietro Iaffaldano, Roberta Lanzillo, Salvatore Lo Fermo, Alessandra Lucisano, Alessandra Lugaresi, Giacomo Lus, Gerolama Alessandra Marfia, Fabiana Marinelli, Massimiliano Mirabella, Lucia Moiola, Chiara Perin, Sabrina Realmuto, Simona Toscano, María Trojano, Domizia Vecchio, Francesco Patti

Article2025

Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-Cd20 Monoclonal Antibodies for Multiple Sclerosis Treatment

Monica Margoni, Luca Battistini, Diego Centonze, Roberto Furlan, Claudio Gasperini, Massimo Filippi

Article2025

Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion

Paolo Preziosa, Vincenzo Brescia Morra, Marco Capobianco, Claudio Gasperini, Luigi Maria Edoardo Grimaldi, Girolama Alessandra Marfia, Damiano Paolicelli, Paola Perini, Valentina Torri Clerici, Massimo Filippi

Article2025

Safety and long-term efficacy of autologous hematopoietic cell transplantation for patients with systemic sclerosis

Eleni Gavriilaki, Despina Mallouri, Ioannis Batsis, Zoi Bousiou, Anna Vardi, Nikolaos Spyridis, Georgios Karavalakis, A. Panteliadou, Panagiotis Dolgyras, Christos Varelas, Vlasios I. Alevizopoulos, Panagiotis Asteris, Panayiotis G. Vlachoyiannopoulos, Damianos Sotiropoulos, Petros P. Sfikakis, Ioanna Sakellari

10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005)

Abstract

Discussion(0)

Related publications

Long-term disability progression in primary progressive multiple sclerosis: a 15-year study

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)

Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-Cd20 Monoclonal Antibodies for Multiple Sclerosis Treatment

Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion

Safety and long-term efficacy of autologous hematopoietic cell transplantation for patients with systemic sclerosis